Navigation Links
Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% : Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases
Date:11/17/2008

Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB, reported positive additional interim results from its ongoing phase I/II clinical study of its therapeutic DNA vaccine against hepatitis C virus (HCV). This vaccine is being delivered using Inovio’s electroporation-based DNA delivery system. In the third and highest dose cohort of the study, two of three subjects demonstrated reductions in viral load of 93% and 99.7%. Previously reported middle dose cohort results demonstrated an 87% and 98% reduction in HCV in two of three subjects, while no anti-viral effect was observed in the low dose cohort. No safety issues have been noted to date in the trial. These data suggest a potential dose response of the vaccine and support the inclusion of three additional subjects in the high dose cohort.

SAN DIEGO (Business Wire EON) November 17, 2008 -- These data where presented by Dr. Matti Sllberg of Tripep at the recent American Association for the Study of Liver Diseases meeting held in San Francisco.

Avtar Dhillon, MD, Inovio's president and CEO, stated: "We continue to be encouraged by the data flowing out of the ChronVac-C study. This promising DNA vaccine candidate, in which Inovio has an ownership position, is one of the more advanced clinical vaccine candidates in the HCV field. ChronVac-C was designed to play a role as a first-line therapy or as an adjunct to existing therapies."

About ChronVac-C

ChronVac-C is a therapeutic DNA-based vaccine given to individuals already infected with the hepatitis C virus with the aim of clearing the infection from the liver by boosting the body's immune response against the virus. Inovio's electroporation technology is being used to deliver the vaccine and is intended to enhance the
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment
2. Roche Receives FDA Approval for Hepatitis C Viral Load Test on Its Fully Automated Real-Time PCR Platform
3. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
4. Why Are Some Veterans Who Are Coinfected With Hepatitis C and HIV More Likely to Be Treated for HCV Than Others?
5. Hepatitis C treatment is cost-effective for the US prison population
6. Existing anti-obesity drugs may be effective against flu, hepatitis and HIV
7. Majority of children vaccinated against hepatitis B not at increased risk of MS
8. How to select anti-hepatitis B virus agents for drug-resistance patients?
9. The prevalence of hepatitis B virus infection in inflammatory bowel disease patients
10. A potential approach to treatment of hepatitis B virus infection
11. New approach, old drug show promise against hepatitis C, Stanford research shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% :  Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases 
(Date:7/9/2014)... stromal support cells and immune cells and the ... the development of diseases could open new therapeutic ... the conclusion of a review article by scientists from ... Nature . , Prof. Peter Carmeliet: "Consider the review ... cancer cells has been examined in minute detail for ...
(Date:7/9/2014)... feelings are personal and subjective, the human brain ... represents emotions across different senses, situations and even ... neuroscientist Adam Anderson. , "We discovered that fine-grained ... an area of the brain associated with emotional ... an individual,s subjective feeling," says Anderson, associate professor ...
(Date:7/9/2014)... for more than watching World Cup highlights, Brian Williams ... landing in unfortunate positions on railings. A University of ... Online Journal shows that YouTube also allows researchers, ... public on topics of skin cancer and prevention. , ... the future of how we communicate around the world," ...
(Date:7/9/2014)... labels handed out by pharmacists may be misread ... according to new research by the University of ... Blind)., The study, published recently in the ... prescription medications dispensed by pharmacies do not consistently ... simply following recommended guidelines for font size, use ...
(Date:7/9/2014)... microbiologists from the Keck School of Medicine of ... that mice lacking a specific component of the ... potentially fatal complication of infection. The discovery suggests ... reduce inflammation in human autoimmune and hyper-inflammatory diseases ... , The study was published online on June ...
Breaking Medicine News(10 mins):Health News:Wake-up call for more research into cell metabolism 2Health News:Study cracks how the brain processes emotions 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... U.S. Department of Energy,s (DOE) Brookhaven National Laboratory have ... design of a "medical synchrotron" capable of delivering precision ... damage to surrounding healthy tissue. The new device would ... systems, potentially increasing the availability and benefits of this ...
... There is a new,Internet service available that changes the ... stay informed, it allows,long-term care providers to give them regular ... text message without families having,to call, no matter where they ... to do and too little time. It,s a common problem ...
... and digital radiography highlighted at RSNA 2008 , ... Siemens Healthcare ( ... from fluoroscopy and digital radiography to interventional radiology, at ... Radiological Society of North America (RSNA) from November 30 ...
... Pharmaceuticals, Inc. (Nasdaq: IDIX ) announced today that ... Conference on Wednesday, December 3, 2008 at 4:30p.m. ET at ... , The live and archived ... of Events" in the Idenix Investor Center at www.idenix.com ...
... Inc.,(Nasdaq: CEPH ) and ImmuPharma PLC (LSE: ... have signed an Option Agreement,providing Cephalon with an option ... Lupuzor(TM) for the treatment of Systemic Lupus,Erythematosus. ImmuPharma ... in patients in Europe and Latin America. , ...
... 25 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... monoclonal antibodies for the treatment of serious ... U.S. Patent and Trademark,Office has issued U.S. ... covering anti-viral applications of antibodies that directly ...
Cached Medicine News:Health News:Physicists receive patent for improved cancer therapy device 2Health News:Physicists receive patent for improved cancer therapy device 3Health News:New Internet Service Delivers Relief to Families of Those in Long-Term Care 2Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 2Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 3Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 4Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 5Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 6Health News:Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication 2Health News:Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication 3Health News:Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication 4Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies 2Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies 3Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies 4
(Date:1/15/2014)... DUBLIN , Jan. 15, 2014  Research and Markets ... "Dental Consumables Market - Global Industry Analysis, Size, ... report to their offering. (Logo: ... products which are used on patients in order to ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... DIEGO, Aug. 12, 2011 / PRNewswire/ -- Halozyme ... company developing and commercializing products targeting the extracellular ... at the Wedbush 2011 Life Sciences Conference in New ... at 9:10 a.m. EDT (6:10 a.m. PDT). To listen ...
... WOODLANDS, Texas, Aug. 11, 2011 Lexicon Pharmaceuticals, ... company focused on discovering breakthrough treatments for human disease, ... , Lexicon,s president and chief executive officer, will present ... on Tuesday, August 16, 2011 at 1:15 p.m. Eastern ...
Cached Medicine Technology:Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17 2Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: